- Home
- IHS vs VIR Comparison
IHS vs VIR Comparison
Compare IHS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- VIR
- Stock Information
- Founded
- IHS 2001
- VIR 2016
- Country
- IHS United Kingdom
- VIR United States
- Employees
- IHS N/A
- VIR N/A
- Industry
- IHS Telecommunications Equipment
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- VIR Health Care
- Exchange
- IHS Nasdaq
- VIR Nasdaq
- Market Cap
- IHS 1.9B
- VIR 706.4M
- IPO Year
- IHS 2021
- VIR 2019
- Fundamental
- Price
- IHS $5.96
- VIR $5.65
- Analyst Decision
- IHS Strong Buy
- VIR Strong Buy
- Analyst Count
- IHS 6
- VIR 8
- Target Price
- IHS $9.75
- VIR $30.25
- AVG Volume (30 Days)
- IHS 900.6K
- VIR 1.2M
- Earning Date
- IHS 08-12-2025
- VIR 07-31-2025
- Dividend Yield
- IHS N/A
- VIR N/A
- EPS Growth
- IHS N/A
- VIR N/A
- EPS
- IHS N/A
- VIR N/A
- Revenue
- IHS $1,733,125,000.00
- VIR $20,861,000.00
- Revenue This Year
- IHS $0.63
- VIR N/A
- Revenue Next Year
- IHS $4.82
- VIR $0.62
- P/E Ratio
- IHS N/A
- VIR N/A
- Revenue Growth
- IHS N/A
- VIR N/A
- 52 Week Low
- IHS $2.44
- VIR $4.32
- 52 Week High
- IHS $6.43
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- IHS 52.82
- VIR 57.21
- Support Level
- IHS $5.40
- VIR $5.20
- Resistance Level
- IHS $6.27
- VIR $6.23
- Average True Range (ATR)
- IHS 0.26
- VIR 0.30
- MACD
- IHS 0.02
- VIR 0.07
- Stochastic Oscillator
- IHS 54.37
- VIR 56.06
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.